Motif Bio Signs Agreement with Lamellar Biomedical

    NEXT STORY
    Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations
    PREV STORY
    Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps

    author_avatar
    NASDAQ Market News

    Generation Bio Appoints Matthew Norkunas, M.D., MBA as Chief Financial Officer

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Reports Second Quarter 2018 Financial Results and Provides Update on Operations

    Key Highlights: Top-line results from confirmatory Phase III study with TALICIA® for H. pylori ...

    author_avatar
    NASDAQ Market News